Home
Clinical Trials
"Baricitinib for Treating Hos...

"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

Last Updated: 2023-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to determine the safety (phase II), then efficacy (phase III) of baricitinib plus standard of care (SOC) as compared to SOC alone for the treatment of hospital-acquired pneumonia in patients with a pro-inflammatory profile.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model

NCT03511105

Healthy Volunteers

TERMINATED PHASE1

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

NCT05531149

Respiratory Infection Pneumonia Community-acquired Pneumonia +5 more

TERMINATED PHASE3

Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

NCT05010876

Covid19

COMPLETED PHASE2

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

NCT00789685

Acute Lung Injury Acute Respiratory Distress Syndrome

COMPLETED PHASE1/PHASE2

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

NCT04389671

COVID-19 Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For both groups :

At inclusion visit :

* Verification of inclusion and non-inclusion criteria
* Patient information and signature of consent form
* Pregnancy test (urine ou blood)
* Randomization
* Clinical evaluation (cardiac frequency, saturation, tracheal secretions, PaO2/FiO2 ratio, body temperature, mechanical ventilation support)
* Collection of respiratory fluid and blood for biobank
* Liver function test (AST, ALT, bilirubin), blood white cells count and EKG
* Treatment compliance
* Concomitant medications (antimicrobial therapy and steriods)
* Survival and EQ-5D-5L

At visit 1 to visit 10 ( Day1- day10)

* Clinical evaluation (cardiac frequency, saturation, tracheal secretions, PaO2/FiO2 ratio, body temperature, mechanical ventilation support)
* Study drug administration (daily)
* Collection of respiratory fluid and blood for biobank (day 3 and day 7)
* Liver function test (AST, ALT, bilirubin), blood white cells count and EKG (Liver, day 3 and day 7)
* Treatment compliance
* Adverse event
* Concomitant medications (antimicrobial therapy and steriods)

At visit 11(Day 10-12 test-of-cure) :

* Clinical evaluation (cardiac frequency, saturation, tracheal secretions, PaO2/FiO2 ratio, body temperature, mechanical ventilation support)
* Collection of respiratory fluid and blood for biobank
* Collection of the respiratory fluid for bacterial cure
* Liver function test (AST, ALT, bilirubin), blood white cells count and EKG
* Adverse event
* Concomitant medications (antimicrobial therapy and steriods)

At visit 12 :

* Adverse event
* Survival and EQ-5D-5L

At visit 13 (month 3) and visit 14 (month 6) :

* Query in NHI Database (SNDS) for consumption of Health resources (pharmaceuticals, consultations...)
* Survival and EQ-5D-5L
* Health -related quality of the life (SF-36), anxiety/depression (HADS), subjective well-being (SWLS)
* Interview with a researcher in pshychology (20 patients and their relatives - only in France)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hospital-acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baricitinib + Standard of care

Baricitinib injected per os for 10 days (4mg/day). the first administration of this treatment is performed within the 6 hours following the randomization, followed by daily administration for a total of 10 days.

The standard of care : for treating HAP will comply with international guidelines. For all patients, empiri antimicrobial therapy is initiated imedialty after collecting the respiratory sample and can thus be started before the randomization to avoid delayed antimicrobial therapy. Its recommanded to broaden the spectrum in case of resistant bacteria resistant to the empirical antimicrobial therapy but il is not recommanded to prolong the antibiotic tratment for more than 7-8 days

Group Type EXPERIMENTAL

Baricitinib 4 MG

Intervention Type DRUG

Reference drug

Standard of care alone

Same as described in arm 1

Group Type SHAM_COMPARATOR

Baricitinib 4 MG

Intervention Type DRUG

Reference drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baricitinib 4 MG

Reference drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ventilators-associated pneumonia (VAP) or hospital -acquired pneumonia requiring invasive ventilation (V-HAP)
* Diagnosis of HAP according to European guidelines : association of two clinical criteria (body temperature \> 38°c and purulent pulmonary secretions), the appearance of a new infiltrate or change in an existing infiltrate on chest radography, and respiratory sample (AET, BAL, mini-BAL or blind BAL) collected for bacteriological diagnosis (results can be pending at inclusion). The diagnosis of HAP can have been made outside of ICU
* VAP : patients should have received machenical ventilation via an endotracheal or nasotracheal tube for the least 48h at the time of HAP diagnosis. V-HAP : patients should have been hospitalized for the least 48 hours before the onset of the first signs or symptoms and required invasive mechanical ventilation during HAP treatment
* Biological systemic inflammatory response defined according to the on-site standard of acre (CPR \> 125 mg/L and/or PCT \> 2µg/L and/or ferritin blood level \> 650 ng/mL
* Receiving antimicrobal therapy for the current episode of HAP pneumonia for less than 72 hours
* Informed consent from legal representative or emergency procedure (when possible according to national regulation). If it's impossible to obtain patient consent before the inclusion (comatose patients), patient consent for the study continuation will be obtained as soon as deemed possible
* Person insured under a helth insurance scheme

Exclusion Criteria

* Pregnant women (serum or urine test), breastfeeding woment
* Patient under legal protection (inc. under guardianship or trusteesheep)
* Hypersensitivity to baricitinib
* Uncontrolled herpes zoster, viral hepatitis, infection with human immunodeficiency virus, fungal infections or tuberculosis
* Severe hepatic insufficiency (child-Pugh B or C)
* Acute or chronic renal insufficiency (modification of diet in renal disease (MDRD) creatinine clearance \< 30 ml/min/1.73 m²)
* Persistent anemia (haemoglobin \< 8 g/L), lymphopenia (absolute lymphocyte \< 500 cells/mm3)
* Immunosuppression (hematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion or anti-graft rejection drug)
* Recent (\<90 days) trhomboembolic event (venous trhombosis, pulmonary embolism, myocardial infarction, and/or stroke)
* Participation to an interventional drug study within 1 month prior to the inclusion

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers